Medical Grand Rounds

*Presented by*

Yale School of Medicine, Department of Internal Medicine,

Section of Pulmonary Critical Care and Sleep Medicine

Lorraine B. Ware MD

Ralph and Lulu Owen Professor of Medicine

Director, Vanderbilt Medical Scholars Program, Vanderbilt University School of Medicine

“Through the Prism: Identifying Treatable Phenotypes in ARDS”

**Date: February 25, 2021 Time: 4:00-5:00pm**

**Location:** [**https://zoom.us/j/94896766303?pwd=UWFrcG9GNXMvcWZ3YU4ycUc5VEVSdz09**](https://zoom.us/j/94896766303?pwd=UWFrcG9GNXMvcWZ3YU4ycUc5VEVSdz09)

***There is no corporate support for this activity***

This course will fulfill the licensure requirement set forth by the State of Connecticut

**ACCREDITATION:**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**TARGET AUDIENCE:**

**Attending physicians, house staff, fellows, medical students, PA’s**

**NEEDS ASSESSMENT:**

Acute Respiratory Distress Syndrome (ARDS) is common in critically ill patients and is associated with high mortality. Clinicians need to understand that ARDS is characterized by clinical and biological heterogeneity and know about distinct clinical phenotypes and genetic risk factors.

**LEARNING OBJECTIVES:**

1. Understand that ARDS is a clinical syndrome that encompasses both clinical and biological heterogeneity

2. Understand how latent class analysis has identified two biologic phenotypes of ARDS

3. Understand the effect of common genetic heterogeneity in the haptoglobin gene on risk of ARDS

**DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY DISCLOSURES:**

Course Director: Vincent Quagliarello, MD - None

Speaker: Lorraine B. Ware, MD-

Boehringer Ingelheim, Consulting fees, Scientific advisor

Merck, Consulting fees, Scientific advisor

Foresee Pharmaceuticals, Consulting fees, Scientific advisor

Citius Pharmaceuticals, Consulting fees, Scientific advisor

CSL Behring, Funds paid to VUMC, Contract for research

Genentech, Funds paid to VUMC, Contract for research

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs